There is an overexpression of HDAC in cancer cells, and the use of HDACis has been shown to enhance the outcomes of individuals who have been diagnosed with haematological malignancies include T-cell lymphomas and multiple myeloma. The gene discussed is HDAC9; the disease is AL amyloidosis.